Acyclic nucleoside phosphonates: A key class of antiviral drugs

被引：561

作者：

De Clercq, E ^{[1
]}

Holy, A

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

[2] Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague, Czech Republic

来源：

NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 11期

关键词：

D O I：

10.1038/nrd1877

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Almost 20 years after the broad antiviral activity spectrum of the first acyclic nucleoside phosphonates was described, several of these compounds have become important therapies for DNA virus and retrovirus infections. Here, we review the discovery and development of acyclic nucleoside phosphonates, focusing on cidofovir and its potential in the treatment of various herpes-, papilloma-, polyoma-, adeno- and pox-virus infections, adefovir for the treatment of hepatitis B and tenofovir for the treatment of AIDS and the prevention of HIV infections.

引用

页码：928 / 940

页数：13

共 157 条

[1] Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers
Abdulkarim, B
Sabri, S
Deutsch, E
Chagraoui, H
Maggiorella, L
Thierry, J
Eschwege, F
Vainchenker, W
Chouaïb, S
Bourhis, J
[J]. ONCOGENE, 2002, 21 (15) : 2334 - 2346
[2] Increased antiviral activity of 1-O-hexadecyloxypropyl-[ 2-14C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism
Aldern, KA
Ciesla, SL
Winegarden, KL
Hostetler, KY
[J]. MOLECULAR PHARMACOLOGY, 2003, 63 (03) : 678 - 681
[3] Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene
Andrei, G
Snoeck, R
De Clercq, E
Esnouf, R
Fiten, P
Opdenakker, G
[J]. JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 639 - 648
[4] Andrei G, 1998, ONCOL RES, V10, P533
[5] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells
Andrei, G
Snoeck, R
Schols, D
De Clercq, E
[J]. ONCOLOGY RESEARCH, 2001, 12 (9-10) : 397 - 408
[6] ANDREI G, 2005, 18 INT C ANT RES BAR
[7] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
Angus, P
Vaughan, R
Xiong, S
Yang, HL
Delaney, W
Gibbs, C
Brosgart, C
Colledge, D
Edwards, R
Ayres, A
Bartholomeusz, A
Locarnini, S
[J]. GASTROENTEROLOGY, 2003, 125 (02) : 292 - 297
[8] MARKED INVIVO ANTIRETROVIRUS ACTIVITY OF 9-(2-PHOSPHONYLMETHOXY-ETHYL)ADENINE, A SELECTIVE ANTI-HUMAN IMMUNODEFICIENCY VIRUS AGENT
BALZARINI, J
NAESENS, L
HERDEWIJN, P
ROSENBERG, I
HOLY, A
PAUWELS, R
BABA, M
JOHNS, DG
DECLERCQ, E
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (01) : 332 - 336
[9] Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates
Balzarini, J
Pannecouque, C
De Clercq, E
Aquaro, S
Perno, CF
Egberink, H
Holy, A
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) : 2185 - 2193
[10] 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines:: A new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity
Balzarini, J
Pannecouque, C
Naesens, L
Andrei, G
Snoeck, R
De Clercq, E
Hocková, D
Holy, A
[J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9) : 1321 - 1327

← 1 2 3 4 5 6 7 8 9 10 →